Participant flow

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma · Source last updated 2018-11-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Phase I Weekly 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide

   id

   FG000

   title

   1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide

2. description

   Phase I Weekly 1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide

   id

   FG001

   title

   1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide

3. description

   Phase I Weekly 1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide

   id

   FG002

   title

   1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide

4. description

   Phase I Weekly 1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide

   id

   FG003

   title

   1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide

5. description

   Phase I Twice Weekly 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide

   id

   FG004

   title

   Dose Level 1- 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid

6. description

   Phase I Twice Weekly 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide

   id

   FG005

   title

   Dose Level 2 - 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid

7. description

   Phase I Twice Weekly 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide

   id

   FG006

   title

   Dose Level 3 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham

8. description

   Phase I Twice Weekly 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide

   id

   FG007

   title

   Dose Level 4 - 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami

9. description

   Phase I Twice Weekly 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide; Pegylated G-CSF

   id

   FG008

   title

   Dose Level 5 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami

10. description

    Phase II Randomized Weekly bortezomib dosing schedule

    id

    FG009

    title

    Weekly Bortezomib Dosing Schedule

11. description

    Phase II Randomized Twice-weekly bortezomib dosing schedule

    id

    FG010

    title

    Twice-weekly Bortezomib Dosing Schedule

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         0

      8. group Id

         FG007

         num Subjects

         0

      9. group Id

         FG008

         num Subjects

         0

      10. group Id

          FG009

          num Subjects

          0

      11. group Id

          FG010

          num Subjects

          1

      type

      Not Treated

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         6

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         4

      5. group Id

         FG004

         num Subjects

         2

      6. group Id

         FG005

         num Subjects

         18

      7. group Id

         FG006

         num Subjects

         3

      8. group Id

         FG007

         num Subjects

         4

      9. group Id

         FG008

         num Subjects

         10

      10. group Id

          FG009

          num Subjects

          12

      11. group Id

          FG010

          num Subjects

          13

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         6

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         4

      5. group Id

         FG004

         num Subjects

         2

      6. group Id

         FG005

         num Subjects

         18

      7. group Id

         FG006

         num Subjects

         3

      8. group Id

         FG007

         num Subjects

         4

      9. group Id

         FG008

         num Subjects

         10

      10. group Id

          FG009

          num Subjects

          12

      11. group Id

          FG010

          num Subjects

          12

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         0

      8. group Id

         FG007

         num Subjects

         0

      9. group Id

         FG008

         num Subjects

         0

      10. group Id

          FG009

          num Subjects

          0

      11. group Id

          FG010

          num Subjects

          1

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice